News

New Jersey, US- based Strativa ,the proprietary products division of a wholly owned subsidiary of Par declared that its development partner, BioAlliance has submitted a New Drug Application

Mylan Pharmaceuticals, a subsidiary of Mylan has received approval from the FDA for supplemental Abbreviated New Drug Application (ANDA) for Temazepam Capsules USP, 22.5 mg. This strength is

The US Federal Trade Commission has granted Johnson & Johnson, the early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act, with respect to its previously

Xcellerex has announced that Crucell is acquiring a FlexFactory bioproduction line and multiple XDR single-use bioreactors, to expand the manufacturing capabilities. The project will deliver new, validated clinical

Global Alliance for TB and Tibotec have enterned into a partnership to accelerate the discovery and development of new drugs for tuberculosis (TB). The two organizations will share

Cepheid has released its improved Xpert BCR-ABL Monitor test, to be marketed as a CE IVD product under the European Directive. It is intended to aid European clinicians

Clavis has announced positive final results from a phase-II trial of its novel investigational cancer drug, elacytarabine (CP-4055), in patients with late-stage acute myeloid leukaemia (AML). Elacytarabine is

CuraGen’s phase I/II trial, evaluating CR011-vcMMAE for the treatment of advanced breast cancer, has met the efficacy criteria for advancement to the second stage of enrollment. CR011-vcMMAE is

Watson Pharmaceuticals has entered into a definitive agreement to acquire Arrow Group for $1.75 billion in cash and stock. The combination of Watson and Arrow will result in